A Japanese venture company and two hospitals will conduct the nation's first clinical trials transplanting genetically modified pig kidneys into kidney failure patients [1].
This initiative seeks to resolve the critical shortage of human organ donors by providing a sustainable, alternative source of viable organs for patients with end-stage renal disease [1, 3].
Pol Med Tech, a startup from Meiji University, announced the plan on July 21 [1]. The company is collaborating with Shonan Kamakura General Hospital in Kanagawa Prefecture and Hokkaido University Hospital in Sapporo to execute the trials [2, 4]. While some reports suggest Shonan Kamakura General Hospital will lead the efforts, other records indicate both institutions will participate in the clinical process [2, 4].
The clinical trials are scheduled to begin in 2028 [2]. The project focuses on using kidneys from pigs that have undergone genetic modification to prevent immediate organ rejection by the human immune system [1].
Medical professionals have expressed optimism regarding the quality of the organs. A surgeon at Shonan Kamakura General Hospital said the kidneys are very clean and the transplantation process should be very easy [1].
The long-term goal is to integrate this procedure into the broader healthcare system. The representative for Pol Med Tech said the goal is for this to become one of the standard treatments by 2033 [1].
Currently, thousands of patients in Japan remain on waiting lists for kidney transplants, a gap the venture hopes to close through biotechnology [3].
“The goal is for this to become one of the standard treatments by 2033.”
The move toward xenotransplantation in Japan reflects a global shift toward genetic engineering to bypass the chronic shortage of human organs. By targeting 2033 for standard treatment, Japan is attempting to move beyond experimental surgery into a scalable medical model, potentially reducing the reliance on dialysis and long-term waiting lists for renal failure patients.
